Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective different smoking cessation products are when combined with counseling to help people quit smoking. The study will focus on three approved products: nicotine replacement therapy, cytisine, and varenicline. Participants will be clients of Sun Life who are current smokers and want to reduce or quit smoking in the next six months. They must be at least 18 years old and live in Ontario, Canada.

During the trial, participants will receive counseling and the cessation products delivered directly to them from a pharmacy over a 12-week period. The study will track how safe and effective these products are, as well as how well participants use them and attend counseling sessions. It's important to note that those who are pregnant, breastfeeding, or currently in another smoking cessation program cannot participate. If you're interested in quitting smoking and meet the eligibility criteria, this study could be a great opportunity to receive support and resources to help you on your journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥18 years)
• • Current cigarette smokers (more than 5 cigarettes per day) who are interested in reducing or quitting in the next 6 months.
• • Able to provide informed consent.
• • Living in Ontario, Canada
• Exclusion Criteria:
• • Contraindications to any of the study medications (NRT, cytisine, varenicline).
• • Actively using one of the study medications in the past 7 days.
• • Actively enrolled in another formal smoking cessation program.
• • Pregnant or breastfeeding individuals.
• • Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
• • Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).